| Document |
Document Title |
|
WO/2012/030907A1 |
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.
|
|
WO/2012/025450A1 |
New phenylamidines are described, having general formula (I) and their use for the control of phytopathogenic fungi.
|
|
WO/2012/020130A1 |
The present invention relates to phenalkylamine derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of s...
|
|
WO/2012/008435A1 |
Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represente...
|
|
WO/2012/004382A1 |
The present invention relates to a new method for preparing ezetimibe comprising a step of cyclizing the compound (4S)-phenyl-3-[(5S)-(4-fluorophenyl)-(2R)-[(1S)-(4-fluorophe
nylamino)-1-(4-nitrophenyl)methyl]-5-hydroxypentanoyl]oxazol
i...
|
|
WO/2012/003436A1 |
Compounds and compositions are described herein for treating post tramatic stress disorder.
|
|
WO/2012/003497A1 |
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), interme...
|
|
WO/2011/158052A1 |
The present invention is directed to nanostructured Ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Ezetimibe according to the invention have an average pa...
|
|
WO/2011/154953A1 |
This invention is directed to a process for the preparation of high yield alkyl or aryl iodide from its corresponding carboxylic acid using N-iodo amides.
|
|
WO/2011/151808A1 |
The invention relates to hexafluoroisopropyl carbamate derivatives of general formula (I): wherein R, Z, A, m and n as defined in the description, in the form of the base or of an addition salt with an acid. The compounds can be used as ...
|
|
WO/2011/145669A1 |
Disclosed are the compound represented by formula (I) which is useful as a therapeutic or prophylactic agent for various partial and/or generalized epileptic seizures, or a salt thereof. [In the formula, ring A and ring B independently r...
|
|
WO/2011/136292A1 |
Provided is a novel low molecular weight compound which inhibits the production of inducible MMPs, in particular MMP-9, rather than the production of constitutive MMP-2. Also provided is a prophylactic and/or therapeutic agent for an aut...
|
|
WO/2011/132712A1 |
Provided is a novel compound that is useful as a medical drug in that said compound displays strong antimicrobial activity against gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant strains thereof, on the basis of ...
|
|
WO/2011/120040A2 |
Novel compounds and methods of treating or preventing thrombosis or a thrombosis-associated disease.
|
|
WO/2011/115613A1 |
Novel methods for the production of enantiomerically pure (EP) β-lactams by decomposition of α-diazo-β-ketoamides using fluorescent light.
|
|
WO/2011/107474A1 |
The instant invention relates to derivatives of formula (I) and their application in therapeutics.
|
|
WO/2011/102514A1 |
A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a prodrug of the compound or the salt, which has an excellent inhibitory activity on long chain fatty acids family member 6 ...
|
|
WO/2011/100090A1 |
A method of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine (ABDNAZ) by reacting DNAZ with bromoacetyl bromide and boron trifluoride etherate in a solvent to produce a mixture comprising ABDNAZ and a salt of DNAZ. Water a...
|
|
WO/2011/098417A1 |
Substituted cyanobutyrates of the formula I in which the variables are defined according to the description, processes and intermediates for preparing the compounds of the formula I and their N-oxides, their agriculturally suitable salts...
|
|
WO/2011/095772A2 |
Compounds of formula (Ia) or (Ib) find application in treating or preventing: (a) infection; (b) immune disorders; (c) neoplasia; (d) an energy utilization disease; (e) a proteostatic disease; or (f) a lysosomal storage disorder.
|
|
WO/2011/095452A1 |
The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
|
|
WO/2011/073211A1 |
Cancer is one of the major causes of death worldwide. Although many advances have been made in the treatment and management of the disease, the existence of chemotherapy-resistance means there is still a great need to develop new strateg...
|
|
WO/2011/071136A1 |
A therapeutic agent for fibromyalgia, comprising a 5-HT2C receptor agonist as an active ingredient.
|
|
WO/2011/070252A1 |
The invention relates to compounds of formula (I), where ALK is an alkylene chain, and W is a grouping (AA) or (BB), where R and R' are as defined in the description. Said compounds are used as antagonists of central histamine H3 receptors.
|
|
WO/2011/057430A1 |
Chiral N-sulfinyl amino acid amide compounds of the following formula (I), their preparation method and use in the asymmetric catalytic reduction of imines are disclosed, wherein the carbon marked * has S-configuration and the sulfur mar...
|
|
WO/2011/053706A1 |
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R1, R2, R3, Ra, and Y are defined herein.
|
|
WO/2011/032291A1 |
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T- type calcium channel activity are disclosed using a series of compounds containing N-acylated cyclic ...
|
|
WO/2011/023667A1 |
The present invention relates to the use of a compound of general formula (I) wherein R1/R2 are independently from each other hydrogen, lower alkyl, -CH2)o-cycloalkyl for o being 0 or 1, or are benzyl or heterocycloalkyl; or R1 and R2 ar...
|
|
WO/2011/019326A2 |
The present invention relates to pharmaceutical formulations comprising a combination of a therapeutic agent with solubility problem and a therapeutic agent with stability problem, and the methods for the preparation thereof, and the use...
|
|
WO/2011/017907A1 |
Preparation of azetidinone compounds and medical use thereof are provided by the present invention. More particularly, azetidinone compounds, shown as formula (I), wherein R1, R2, R3, R4, R5, R6 are defined in description, and preparatio...
|
|
WO/2011/012810A1 |
The invention relates to 2-amino-2-phenyl-alkanol-derived esters of general formula (I), where: R1 forms, with R3 and the nitrogen and carbon atoms to which they are respectively attached, a 4- to 7-membered heterocyclic compound, option...
|
|
WO/2011/010891A2 |
The present invention relates to a novel post metallocene-type ligand compound, to a metal compound containing the ligand compound, to a catalytic composition containing the metal compound, and to a method for preparing same, as well as ...
|
|
WO/2011/000212A1 |
A preparation method for ezetimibe and intermediates thereof are disclosed. More specifically, compounds shown as the following general formula (I), preparation method, intermediates in the preparation process and use thereof are disclos...
|
|
WO/2010/149888A1 |
Compounds of formula (I) in which: R1 represents a hydrogen atom or a group of formula COR4, or else R1 represents a group of formula (A); R2 represents a group of formula NR5R6, or else R2 represents a nitrogen-containing heterocyclic, ...
|
|
WO/2010/146299A1 |
The invention relates to the compounds of formula (I), where: R is a (C1-C6)alkyl or halo(C1-C6)alkyl group; A is a carbon atom optionally substituted by one or more hydrogen atoms or (C1-C6)alkyl groups; R5 is one or two carbon atoms su...
|
|
WO/2010/142836A1 |
The present invention relates to the synthesis of intermediates that can be used in TTX synthesis and to the preparation thereof.
|
|
WO/2010/142650A1 |
The invention relates to compounds of formula (I) wherein A1, R1, R2, R3, R4 and R5 are defined in the description and in the claims, which are preferential inhibitors of the cysteine protease cathepsin, in particular of the cysteine pro...
|
|
WO/2010/142241A1 |
High penetration comp1ositions (HPCs) or prodrugs (HPPs) of antimicrobials and antimicrobial-related compounds are provided. The HPCs/HPPs are capable of being converted to parent drugs or drug metabolites after crossing the biological b...
|
|
WO/2010/141494A2 |
The present disclosure relates to processes for the preparation of Ezetimibe (1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypro
pyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone) and related azetidine compounds.
|
|
WO/2010/124112A1 |
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Y, Z, R1, and s are defined herein.
|
|
WO/2010/124114A1 |
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) wherein Y, Z, R1, and s are defined herein.
|
|
WO/2010/124086A1 |
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) wherein Y, Z, R1, and s are defined herein.
|
|
WO/2010/124108A1 |
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Y, Z, R1, and s are defined herein.
|
|
WO/2010/124116A1 |
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: Formula (I) wherein Y, Z, R1, and s are defin...
|
|
WO/2010/121046A1 |
The present invention comprises compounds of Formula (I) wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, w...
|
|
WO/2010/120935A1 |
Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to t...
|
|
WO/2010/113182A1 |
The process of the present invention relates to a method for the synthesis of a 1,4-diphenylazetidinone of formula (VIII) by using novel oxime intermediates.
|
|
WO/2010/113860A1 |
Disclosed is a novel compound that has an antagonist action on a calcium receptor. Specifically disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, the substituents ...
|
|
WO/2010/097350A1 |
The invention relates to a process for the preparation of an aldehyde beta-lactam compound of formula (I), wherein P1 is H or a protecting group, useful in the preparation of ezetimibe, from a nitrone compound of formula (II). The nitron...
|
|
WO/2010/093706A2 |
Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound.
|
